# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) ("Lipella," "our," "us," "we" or the "Company...
Lipella Pharmaceuticals Inc. ("Lipella" or the "Company") (NASDAQ:LIPO), a clinical-stage biotechnology company...
Lipella Pharmaceuticals shares are trading higher Monday after the company announced the enrollment of the first patients in it...
LGVN: 49% | Longeveron Announced Study Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B In Mild Alzheimer's Di...
Lipella's Phase 2a trial is a multi-center, dose-ranging study of LP-310, a proprietary liposomal-tacrolimus oral rinse for...